Pub Date : 2019-03-31DOI: 10.4285/JKSTN.2019.33.1.6
Hyeyoung Lee, E. Oh
Angiotensin II type 1 receptor (AT1R) antibodies directly injure endothelial and vascular smooth muscle cells by activating transcription factors associated with proinflammatory responses. Previous studies have shown that AT1R antibodies are associated with allograft rejection and decreased graft survival in kidney transplantation. Development of enzyme-linked immunosorbent assay has facilitated semiquantitative detection of AT1R antibodies. Assessing AT1R antibodies along with donor specific human leukocyte antigen antibodies may have potential to identify patients with possible risk for allograft injury and improve overall outcomes. In this review, we summarize recent clinical studies about AT1R antibodies in kidney transplantation and provide perspectives for future research area.
{"title":"Angiotensin II type 1 receptor antibodies in kidney transplantation","authors":"Hyeyoung Lee, E. Oh","doi":"10.4285/JKSTN.2019.33.1.6","DOIUrl":"https://doi.org/10.4285/JKSTN.2019.33.1.6","url":null,"abstract":"Angiotensin II type 1 receptor (AT1R) antibodies directly injure endothelial and vascular smooth muscle cells by activating transcription factors associated with proinflammatory responses. Previous studies have shown that AT1R antibodies are associated with allograft rejection and decreased graft survival in kidney transplantation. Development of enzyme-linked immunosorbent assay has facilitated semiquantitative detection of AT1R antibodies. Assessing AT1R antibodies along with donor specific human leukocyte antigen antibodies may have potential to identify patients with possible risk for allograft injury and improve overall outcomes. In this review, we summarize recent clinical studies about AT1R antibodies in kidney transplantation and provide perspectives for future research area.","PeriodicalId":420886,"journal":{"name":"The Journal of The Korean Society for Transplantation","volume":"29 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2019-03-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"131126797","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-03-01DOI: 10.4285/JKSTN.2019.33.1.1
Sanghoon Lee, S. Lee
Pediatric liver transplantation has evolved into an effective treatment for a variety of liver diseases in the pediatric population. Over the past 25 years, pediatric liver transplantation results in Korea have matched international standards, and Korea has become one of the most important leaders in living donor liver transplantation. This review presents the cumulative outcomes of pediatric liver transplants in Korea and highlights other concerns related to pediatric liver transplantation, particularly pediatric liver allocation policy and split liver transplantation.
{"title":"Pediatric liver transplantation in Korea: long-term outcomes and allocations","authors":"Sanghoon Lee, S. Lee","doi":"10.4285/JKSTN.2019.33.1.1","DOIUrl":"https://doi.org/10.4285/JKSTN.2019.33.1.1","url":null,"abstract":"Pediatric liver transplantation has evolved into an effective treatment for a variety of liver diseases in the pediatric population. Over the past 25 years, pediatric liver transplantation results in Korea have matched international standards, and Korea has become one of the most important leaders in living donor liver transplantation. This review presents the cumulative outcomes of pediatric liver transplants in Korea and highlights other concerns related to pediatric liver transplantation, particularly pediatric liver allocation policy and split liver transplantation.","PeriodicalId":420886,"journal":{"name":"The Journal of The Korean Society for Transplantation","volume":"6 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2019-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"127344563","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-03-01DOI: 10.4285/JKSTN.2019.33.1.13
Heeryong Lee, J. An, D. R. Lee, Hyung Wook Choi, J. Oh, Joong-Kyung Kim
This is a case of a 56-year-old man with Castleman disease (CD) who improved after kidney transplantation (KTP). CD is an uncommon lymphoproliferative disorder that was found incidentally on biopsy during dialysis in the current patient and was followed up without further treatment. However, the lesion showed improvement after KTP. Therefore, active KTP can be considered even if CD is one of the lymphoproliferative disorders that can occur as a complication after KTP.
{"title":"A case of Castleman disease that improved after kidney transplantation","authors":"Heeryong Lee, J. An, D. R. Lee, Hyung Wook Choi, J. Oh, Joong-Kyung Kim","doi":"10.4285/JKSTN.2019.33.1.13","DOIUrl":"https://doi.org/10.4285/JKSTN.2019.33.1.13","url":null,"abstract":"This is a case of a 56-year-old man with Castleman disease (CD) who improved after kidney transplantation (KTP). CD is an uncommon lymphoproliferative disorder that was found incidentally on biopsy during dialysis in the current patient and was followed up without further treatment. However, the lesion showed improvement after KTP. Therefore, active KTP can be considered even if CD is one of the lymphoproliferative disorders that can occur as a complication after KTP.","PeriodicalId":420886,"journal":{"name":"The Journal of The Korean Society for Transplantation","volume":"49 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2019-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"134370870","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2018-12-31DOI: 10.4285/JKSTN.2018.32.4.108
Boram Lee, Soomin Ahn, Haeryoung Kim, Ho-Seong Han, Yoo-Seok Yoon, J. Cho, Y. Choi
Donor Specific Antibody Negative Antibody-Mediated Rejection after ABO Incompatible Liver Transplantation Boram Lee, M.D., Soomin Ahn, M.D., Haeryoung Kim, Ph.D., Ho-Seong Han, Ph.D., Yoo-Seok Yoon, Ph.D., Jai Young Cho, Ph.D. and Young Rok Choi, M.D. Departments of Surgery and Pathology, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Department of Pathology, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea
{"title":"Donor Specific Antibody Negative Antibody-Mediated Rejection after ABO Incompatible Liver Transplantation","authors":"Boram Lee, Soomin Ahn, Haeryoung Kim, Ho-Seong Han, Yoo-Seok Yoon, J. Cho, Y. Choi","doi":"10.4285/JKSTN.2018.32.4.108","DOIUrl":"https://doi.org/10.4285/JKSTN.2018.32.4.108","url":null,"abstract":"Donor Specific Antibody Negative Antibody-Mediated Rejection after ABO Incompatible Liver Transplantation Boram Lee, M.D., Soomin Ahn, M.D., Haeryoung Kim, Ph.D., Ho-Seong Han, Ph.D., Yoo-Seok Yoon, Ph.D., Jai Young Cho, Ph.D. and Young Rok Choi, M.D. Departments of Surgery and Pathology, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Department of Pathology, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea","PeriodicalId":420886,"journal":{"name":"The Journal of The Korean Society for Transplantation","volume":"23 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2018-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"127715487","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2018-12-01DOI: 10.4285/JKSTN.2018.32.4.104
H. Kim, S. Han, H. Park, Hyun-woo Kim, R. Hong, N. Choi, M. Shin, N. Yoon, Hyun Lee Kim, J. Chung, B. Shin
Type : Poster Presentation No. : PTL 031 Successful treatment of invasive gastric mucormycosis in kidney transplant recipient Hyun Woo Kim, Ha Yeol Park, Hyun Lee Kim, Jong Hoon Chung, Byung Chul Shin Department of Internal Medicine-Nephrology, Chosun University Hospital, Korea, Republic of Case Study: Mucormycosis is an extremely rare, but potentially life-threatening fungal infection. Gastrointestinal (GI) mucormycosis is rare and occurs primarily in the extremely malnourished patients especially infants or children. A 55-year-old man with end-stage renal disease due to diabetic nephropathy underwent deceased donor kidney transplantation on 2years ago. He complained of abdominal pain and distension on 3days ago at admission. A computed tomography (CT) scan revealed diffuse gastric wall thickening. A gastrointestinal (GI) endoscopy showed huge grey colored elevated necrotic debris surrounded by erythematous erosive mucosa at antrum to upper body. Microscopic examination obtained from a GI endoscopic specimen demonstrated peptic detritus with numerous nonseptate mucor hyphae was noted in the mucosa and submucosa. Mucormycosis was diagnosed according to the clinical findings and morphological features. A total gastrectomy was performed and antifungal agent was supplied. Microscopic examination obtained from a surgical specimen demonstrated invasive mucormycosis with numerous fungal hyphae with invasion into mucosa to subserosa. The patient and graft successfully treated to the infection with total gastrectomy and antifungal therapy. GI endocscopy showed gastric mucormycosis
{"title":"Successful Treatment of Invasive Gastric Mucormycosis in a Kidney Transplant Recipient","authors":"H. Kim, S. Han, H. Park, Hyun-woo Kim, R. Hong, N. Choi, M. Shin, N. Yoon, Hyun Lee Kim, J. Chung, B. Shin","doi":"10.4285/JKSTN.2018.32.4.104","DOIUrl":"https://doi.org/10.4285/JKSTN.2018.32.4.104","url":null,"abstract":"Type : Poster Presentation No. : PTL 031 Successful treatment of invasive gastric mucormycosis in kidney transplant recipient Hyun Woo Kim, Ha Yeol Park, Hyun Lee Kim, Jong Hoon Chung, Byung Chul Shin Department of Internal Medicine-Nephrology, Chosun University Hospital, Korea, Republic of Case Study: Mucormycosis is an extremely rare, but potentially life-threatening fungal infection. Gastrointestinal (GI) mucormycosis is rare and occurs primarily in the extremely malnourished patients especially infants or children. A 55-year-old man with end-stage renal disease due to diabetic nephropathy underwent deceased donor kidney transplantation on 2years ago. He complained of abdominal pain and distension on 3days ago at admission. A computed tomography (CT) scan revealed diffuse gastric wall thickening. A gastrointestinal (GI) endoscopy showed huge grey colored elevated necrotic debris surrounded by erythematous erosive mucosa at antrum to upper body. Microscopic examination obtained from a GI endoscopic specimen demonstrated peptic detritus with numerous nonseptate mucor hyphae was noted in the mucosa and submucosa. Mucormycosis was diagnosed according to the clinical findings and morphological features. A total gastrectomy was performed and antifungal agent was supplied. Microscopic examination obtained from a surgical specimen demonstrated invasive mucormycosis with numerous fungal hyphae with invasion into mucosa to subserosa. The patient and graft successfully treated to the infection with total gastrectomy and antifungal therapy. GI endocscopy showed gastric mucormycosis","PeriodicalId":420886,"journal":{"name":"The Journal of The Korean Society for Transplantation","volume":"89 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2018-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"123497942","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2018-12-01DOI: 10.4285/JKSTN.2018.32.4.84
Seung Hoon Lee, H. Choi, Y. You, D. G. Kim, G. Na
Background: This study examined the outcomes of ABO incompatible living donor liver transplantation (LDLT). The changes in the immunologic factors that might help predict the long term outcomes were also studied. Methods: Twenty-three patients, who underwent ABO incompatible LDLT from 2010 to 2015, were reviewed retrospectively. The protocol was the same as for ABO compatible LDLT except for the administration of rituximab and plasma exchange. The clinical outcomes and immunologic factors, such as isoagglutinin titer and cluster of differentiation 20+ (CD20+) lymphocyte levels were reviewed. Results: The center showed a 3-year survival of 64% with no case of antibody-mediated rejection. When transplantation-unrelated mortalities (for example, traffic accidents and myocardial infarction) were removed from statistical analysis, the 3-year survival was 77.8%. Although isoagglutinin titers continued to remain at low levels, the CD20+ lymphocyte levels recovered to the pre-Rituximab levels at postoperative one year. Conclusions: As donor shortages continue, ABO incompatible liver transplantation is a feasible method to expand the donor pool. On the other hand, caution is still needed until more long-term outcomes are reported. Because CD20+ lymphocytes are recovered with time, more immunologic studies will be needed in the future.
{"title":"ABO Incompatible Living Donor Liver Transplantation: A Single Center Experience","authors":"Seung Hoon Lee, H. Choi, Y. You, D. G. Kim, G. Na","doi":"10.4285/JKSTN.2018.32.4.84","DOIUrl":"https://doi.org/10.4285/JKSTN.2018.32.4.84","url":null,"abstract":"Background: This study examined the outcomes of ABO incompatible living donor liver transplantation (LDLT). The changes in the immunologic factors that might help predict the long term outcomes were also studied. Methods: Twenty-three patients, who underwent ABO incompatible LDLT from 2010 to 2015, were reviewed retrospectively. The protocol was the same as for ABO compatible LDLT except for the administration of rituximab and plasma exchange. The clinical outcomes and immunologic factors, such as isoagglutinin titer and cluster of differentiation 20+ (CD20+) lymphocyte levels were reviewed. Results: The center showed a 3-year survival of 64% with no case of antibody-mediated rejection. When transplantation-unrelated mortalities (for example, traffic accidents and myocardial infarction) were removed from statistical analysis, the 3-year survival was 77.8%. Although isoagglutinin titers continued to remain at low levels, the CD20+ lymphocyte levels recovered to the pre-Rituximab levels at postoperative one year. Conclusions: As donor shortages continue, ABO incompatible liver transplantation is a feasible method to expand the donor pool. On the other hand, caution is still needed until more long-term outcomes are reported. Because CD20+ lymphocytes are recovered with time, more immunologic studies will be needed in the future.","PeriodicalId":420886,"journal":{"name":"The Journal of The Korean Society for Transplantation","volume":"29 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2018-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"124512694","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2018-12-01DOI: 10.4285/JKSTN.2018.32.4.92
Ho Lee, A. Han, Chanjoong Choi, Sanghyun Ahn, S. Min, S. Min, Hajeong Lee, Y. S. Kim, J. Yang, J. Ha
Background: Currently, trimethoprim-sulfamethoxazole is used for Pneumocystis jirovecii pneumonia (PJP) prophylaxis, but it is associated with frequent adverse effects. This study evaluated the efficacy and safety of the current protocol and proposes an individualized risk-based prophylaxis protocol. Methods: The PJP incidence and risk factors during the first 6 months (early PJP) and afterwards (late PJP) was assessed in renal transplant recipients with (prophylaxis group) and without (no-prophylaxis group) 6-month PJP prophylaxis. Results: In 578 patients, there were 39 cases of PJP during a median follow-up of 51 months. Renal adverse events were encountered frequently during trimethoprim-sulfamethoxazole prophylaxis, leading to premature discontinuation. Patients without the prophylaxis had a significantly higher incidence of early PJP (n=27, 6.6%) compared to patients with the prophylaxis (n=0). The incidence of late PJP was 2.2%, without between-group differences. The factors associated with early PJP were preoperative desensitization and acute rejection within 1 month, whereas late PJP was associated with age, deceased donor transplant, and acute rejection requiring antithymocyte globulin treatment. Conclusions: Based on the simulation results of several risk-based scenarios, the authors recommend universal prophylaxis up to 6 months post-transplant and extended selective prophylaxis in patients aged ≥ 57 years and those with a transplant from deceased donors.
{"title":"Proposal of a Selective Prophylaxis Strategy Based on Risk Factors to Prevent Early and Late Pneumocystis jirovecii Pneumonia after Renal Transplantation","authors":"Ho Lee, A. Han, Chanjoong Choi, Sanghyun Ahn, S. Min, S. Min, Hajeong Lee, Y. S. Kim, J. Yang, J. Ha","doi":"10.4285/JKSTN.2018.32.4.92","DOIUrl":"https://doi.org/10.4285/JKSTN.2018.32.4.92","url":null,"abstract":"Background: Currently, trimethoprim-sulfamethoxazole is used for Pneumocystis jirovecii pneumonia (PJP) prophylaxis, but it is associated with frequent adverse effects. This study evaluated the efficacy and safety of the current protocol and proposes an individualized risk-based prophylaxis protocol. Methods: The PJP incidence and risk factors during the first 6 months (early PJP) and afterwards (late PJP) was assessed in renal transplant recipients with (prophylaxis group) and without (no-prophylaxis group) 6-month PJP prophylaxis. Results: In 578 patients, there were 39 cases of PJP during a median follow-up of 51 months. Renal adverse events were encountered frequently during trimethoprim-sulfamethoxazole prophylaxis, leading to premature discontinuation. Patients without the prophylaxis had a significantly higher incidence of early PJP (n=27, 6.6%) compared to patients with the prophylaxis (n=0). The incidence of late PJP was 2.2%, without between-group differences. The factors associated with early PJP were preoperative desensitization and acute rejection within 1 month, whereas late PJP was associated with age, deceased donor transplant, and acute rejection requiring antithymocyte globulin treatment. Conclusions: Based on the simulation results of several risk-based scenarios, the authors recommend universal prophylaxis up to 6 months post-transplant and extended selective prophylaxis in patients aged ≥ 57 years and those with a transplant from deceased donors.","PeriodicalId":420886,"journal":{"name":"The Journal of The Korean Society for Transplantation","volume":"32 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2018-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"126345605","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2018-12-01DOI: 10.4285/JKSTN.2018.32.4.75
J. Rhu, Kyo-Won Lee, J. Park, Sung Joo Kim
Background: This study was designed to analyze the clinical usefulness of mycophenolic acid trough concentration monitoring in kidney transplantation patients who were maintained with cyclosporine. Methods: The data of patients who underwent mycophenolic acid trough concentration monitoring after their first kidney transplant between November 2006 and August 2013 and were prescribed with cyclosporine, mycophenolate, and methylprednisolone were reviewed retrospectively. Cox analysis was used to analyze the risk factors for acute rejection within 1 year post-transplantation. Results: Among 90 patients, 41 (45.6%) achieved both the target levels of cyclosporine and mycophenolic acid, while three patients (3.3%) failed to achieve the target level of either cyclosporine or mycophenolic acid. Nine patients (10.0%) only achieved the mycophenolic acid target level and 37 patients (41.1%) only achieved the cyclosporine target level. While patients who achieved only the mycophenolic acid target concentration had no statistically increased risk compared to patients who achieved both target levels (hazard ratio [HR], 1.569; 95% confidence interval [CI], 0.316 to 7.778; P=0.581), patients who only achieved the cyclosporine target concentration showed an increased risk of rejection compared to the both achievement group (HR, 4.112; 95% CI, 1.583 to 10.683; P=0.004). Patients who had no achievement in the target levels showed significantly increased rejection risk compared to the patients who achieved both target levels (HR, 17.811; 95% CI, 3.072 to 103.28; P=0.001). Conclusions: Mycophenolic acid trough concentration monitoring combined with cyclosporine trough concentration monitoring is useful for avoiding acute cellular rejection if the first 1 year post-transplantation.
{"title":"Monitoring of Mycophenolic Acid Trough Concentration in Kidney Transplant under Cyclosporine Is Beneficial in Reducing Acute Rejection within 1 Year","authors":"J. Rhu, Kyo-Won Lee, J. Park, Sung Joo Kim","doi":"10.4285/JKSTN.2018.32.4.75","DOIUrl":"https://doi.org/10.4285/JKSTN.2018.32.4.75","url":null,"abstract":"Background: This study was designed to analyze the clinical usefulness of mycophenolic acid trough concentration monitoring in kidney transplantation patients who were maintained with cyclosporine. Methods: The data of patients who underwent mycophenolic acid trough concentration monitoring after their first kidney transplant between November 2006 and August 2013 and were prescribed with cyclosporine, mycophenolate, and methylprednisolone were reviewed retrospectively. Cox analysis was used to analyze the risk factors for acute rejection within 1 year post-transplantation. Results: Among 90 patients, 41 (45.6%) achieved both the target levels of cyclosporine and mycophenolic acid, while three patients (3.3%) failed to achieve the target level of either cyclosporine or mycophenolic acid. Nine patients (10.0%) only achieved the mycophenolic acid target level and 37 patients (41.1%) only achieved the cyclosporine target level. While patients who achieved only the mycophenolic acid target concentration had no statistically increased risk compared to patients who achieved both target levels (hazard ratio [HR], 1.569; 95% confidence interval [CI], 0.316 to 7.778; P=0.581), patients who only achieved the cyclosporine target concentration showed an increased risk of rejection compared to the both achievement group (HR, 4.112; 95% CI, 1.583 to 10.683; P=0.004). Patients who had no achievement in the target levels showed significantly increased rejection risk compared to the patients who achieved both target levels (HR, 17.811; 95% CI, 3.072 to 103.28; P=0.001). Conclusions: Mycophenolic acid trough concentration monitoring combined with cyclosporine trough concentration monitoring is useful for avoiding acute cellular rejection if the first 1 year post-transplantation.","PeriodicalId":420886,"journal":{"name":"The Journal of The Korean Society for Transplantation","volume":"28 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2018-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"130055799","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2018-09-01DOI: 10.4285/JKSTN.2018.32.3.49
So-Jeong Kim, K. Jun, J. Hwang, B. Chung, Chul-woo Yang, I. Moon, Ji-Il Kim, Mi-hyeong Kim
The Effect of Bortezomib on the Management of Immediate Postoperative Refractory Antibody-Mediated Rejection after Kidney Transplantation So-Jeong Kim, M.D., Kang-Woong Jun, M.D., Jeong-Kye Hwang, M.D., Byung-Ha Chung, M.D., Chul-Woo Yang, M.D., In-Sung Moon, M.D., Ji-il Kim, M.D. and Mi-Hyeong Kim, M.D. Division of Vascular and Transplant Surgery, Department of Surgery, Division of Nephrology, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, Korea
{"title":"The Effect of Bortezomib on the Management of Immediate Postoperative Refractory Antibody-Mediated Rejection after Kidney Transplantation","authors":"So-Jeong Kim, K. Jun, J. Hwang, B. Chung, Chul-woo Yang, I. Moon, Ji-Il Kim, Mi-hyeong Kim","doi":"10.4285/JKSTN.2018.32.3.49","DOIUrl":"https://doi.org/10.4285/JKSTN.2018.32.3.49","url":null,"abstract":"The Effect of Bortezomib on the Management of Immediate Postoperative Refractory Antibody-Mediated Rejection after Kidney Transplantation So-Jeong Kim, M.D., Kang-Woong Jun, M.D., Jeong-Kye Hwang, M.D., Byung-Ha Chung, M.D., Chul-Woo Yang, M.D., In-Sung Moon, M.D., Ji-il Kim, M.D. and Mi-Hyeong Kim, M.D. Division of Vascular and Transplant Surgery, Department of Surgery, Division of Nephrology, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, Korea","PeriodicalId":420886,"journal":{"name":"The Journal of The Korean Society for Transplantation","volume":"1 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2018-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"123723954","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2018-09-01DOI: 10.4285/JKSTN.2018.32.3.57
W. Do, Jonghyo Lee, Kyung Joo Kim, Man-Hoon Han, Hee-Yeon Jung, Ji-Young Choi, Sun-Hee Park, Yong-Lim Kim, Chan-Duck Kim, Jang-Hee Cho, Youngae Yang, Min-Ji Kim, I. Hwang, Kyu Yeun Kim, T. Yim, Yong Jin Kim
Wonseok Do, M.D., Jong-Hak Lee, M.D., Kyung Joo Kim, M.D., Man-Hoon Han, M.D., Hee-Yeon Jung, M.D., Ji-Young Choi, M.D., Sun-Hee Park, M.D., Yong-Lim Kim, M.D., Chan-Duck Kim, M.D., Jang-Hee Cho, M.D., Youngae Yang, M.D., Minjung Kim, M.D., Inryang Hwang, M.D., Kyu Yeun Kim, M.D., Taehoon Yim, M.D. and Yong-Jin Kim, M.D. Department of Internal Medicine, School of Medicine, Kyungpook National University, Department of Internal Medicine, Daegu Fatima Hospital, Department of Pathology, Yeungnam University Medical Center, Yeungnam University College of Medicine, Department of Pathology, School of Medicine, Kyungpook National University, Daegu, Korea
{"title":"Bortezomib Treatment for Refractory Antibody-Mediated Rejection Superimposed with BK Virus-Associated Nephropathy during the Progression of Recurrent C3 Glomerulonephritis","authors":"W. Do, Jonghyo Lee, Kyung Joo Kim, Man-Hoon Han, Hee-Yeon Jung, Ji-Young Choi, Sun-Hee Park, Yong-Lim Kim, Chan-Duck Kim, Jang-Hee Cho, Youngae Yang, Min-Ji Kim, I. Hwang, Kyu Yeun Kim, T. Yim, Yong Jin Kim","doi":"10.4285/JKSTN.2018.32.3.57","DOIUrl":"https://doi.org/10.4285/JKSTN.2018.32.3.57","url":null,"abstract":"Wonseok Do, M.D., Jong-Hak Lee, M.D., Kyung Joo Kim, M.D., Man-Hoon Han, M.D., Hee-Yeon Jung, M.D., Ji-Young Choi, M.D., Sun-Hee Park, M.D., Yong-Lim Kim, M.D., Chan-Duck Kim, M.D., Jang-Hee Cho, M.D., Youngae Yang, M.D., Minjung Kim, M.D., Inryang Hwang, M.D., Kyu Yeun Kim, M.D., Taehoon Yim, M.D. and Yong-Jin Kim, M.D. Department of Internal Medicine, School of Medicine, Kyungpook National University, Department of Internal Medicine, Daegu Fatima Hospital, Department of Pathology, Yeungnam University Medical Center, Yeungnam University College of Medicine, Department of Pathology, School of Medicine, Kyungpook National University, Daegu, Korea","PeriodicalId":420886,"journal":{"name":"The Journal of The Korean Society for Transplantation","volume":"79 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2018-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"117221141","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：